title: A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors.
abstract: BACKGROUND
  This phase I study determined the maximum tolerated dose (MTD) of AUY922 with capecitabine in advanced solid tumors.
  
  
  METHODS
  Capecitabine 1000 mg/m(2) PO BID was administered with escalating doses of AUY922 IV; the MTD of AUY922 was combined with capecitabine 1250 mg/m(2) (DL6).
  
  
  RESULTS
  23 patients were treated at 5 dose levels (22 mg/m(2)-70 mg/m(2)). No DLTs were observed until DL6 (grade 3 diarrhea). Reversible vision darkening was seen in 26%. Four patients had partial response; 2 previously progressed on fluorouracil. Eight patients had stable disease (median 25.5 weeks).
  
  
  CONCLUSIONS
  AUY922 plus capecitabine was well-tolerated up to 70 mg/m(2) with encouraging preliminary efficacy.
authors.affiliation: a Sarah Cannon Research Institute/Tennessee Oncology , PLLC, Nashville , Tennessee , USA.
authors.forename: Johanna C
authors.initials: JC
authors.lastname: Bendell
authors.affiliation: b Sarah Cannon Research Institute , Nashville , Tennessee , USA.
authors.forename: Suzanne F
authors.initials: SF
authors.lastname: Jones
authors.affiliation: c Florida Cancer Specialists/SCRI , Ft. Myers, Florida , USA.
authors.forename: Lowell
authors.initials: L
authors.lastname: Hart
authors.affiliation: d Oklahoma University/SCRI , Oklahoma City , Oklahoma , USA.
authors.forename: Shubham
authors.initials: S
authors.lastname: Pant
authors.affiliation: e Tennessee Oncology, PLLC/SCRI , Nashville , Tennessee , USA.
authors.forename: Adil
authors.initials: A
authors.lastname: Moyhuddin
authors.affiliation: b Sarah Cannon Research Institute , Nashville , Tennessee , USA.
authors.forename: Cassie M
authors.initials: CM
authors.lastname: Lane
authors.affiliation: b Sarah Cannon Research Institute , Nashville , Tennessee , USA.
authors.forename: Chris
authors.initials: C
authors.lastname: Earwood
authors.affiliation: e Tennessee Oncology, PLLC/SCRI , Nashville , Tennessee , USA.
authors.forename: Patrick
authors.initials: P
authors.lastname: Murphy
authors.affiliation: e Tennessee Oncology, PLLC/SCRI , Nashville , Tennessee , USA.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Patton
authors.affiliation: e Tennessee Oncology, PLLC/SCRI , Nashville , Tennessee , USA.
authors.forename: William C
authors.initials: WC
authors.lastname: Penley
authors.affiliation: e Tennessee Oncology, PLLC/SCRI , Nashville , Tennessee , USA.
authors.forename: Dana
authors.initials: D
authors.lastname: Thompson
authors.affiliation: e Tennessee Oncology, PLLC/SCRI , Nashville , Tennessee , USA.
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Infante
mesh_terms: D000328:Adult; D000368:Aged; D000069287:Capecitabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012118:Resorcinols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: C528044:5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide; D018841:HSP90 Heat-Shock Proteins; D007555:Isoxazoles; D012118:Resorcinols; D000069287:Capecitabine
keywords: AUY922; Capecitabine; Hsp90